期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小细胞肺癌c-Kit基因蛋白的表达及其与预后的关系 被引量：2

The Expression of C-Kit in Small Cell Lung Cancer and Its Prognostic and Therapeutic Implications
下载PDF
导出
摘要 目的:探讨c-Kit基因蛋白在小细胞肺癌(SCLC)中的表达及其与临床病理、预后的关系。方法:采用免疫组化方法,检测63例手术切除SCLC中c-Kit蛋白的表达,并分析其与患者的生存率及其它相关临床资料的关系。结果:63例c-Kit蛋白的阳性表达率为56%(35/63)。c-Kit蛋白的表达与SCLC患者性别、年龄、肿瘤分期以及生存率无明显相关。结论:SCLC的发生发展与c-Kit基因蛋白表达密切相关;与SCLC患者预后尚无确切的相关性。 Objective: To investigate the effect of the expression of c-Kit protein and its relationship between the clinical pathology and the prognosis of small cell lung cancer (SCLC). Methods: Immunohistochemical technique was used to detect the expression of c-Kit protein in 63 patients with SCLC. Results: The positive expression of c-Kit protein was 56% (35/63). There was no obvious correlation between the expression of c-Kit protein and the sex?age?stage and survival rate of the patients with SCLC. Conclusions: The SCLC expression and the c-Kit protein have further confirmed that there is a close correlation between the development of SCLC and the expression of c-Kit protein, which does not exactly correlate to the prognosis of patients with SCLC. We need to get more samples to perform further studies. Previously established anti-c-Kit effects of STI-571 on SCLC cell lines and our observations will supply a new method for clinical therapy of SCLC.
作者 孙蕾娜 哈斯 战忠利
机构地区 津市肿瘤医院肿瘤研究所病理科 内蒙古锡林郭勒盟医院
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2005年第2期87-88,91,共3页 Chinese Journal of Clinical Oncology
关键词 小细胞肺癌 c-Kit基因蛋白 免疫组化 预后 Small Cell Lung Cancer c-Kit IHC Prognosis
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1ChuteJP, Chen T, Feigal E, et al. Twenty years of phase Ⅲ trials for patients with extensive-stage small-cell lung cancer: perceptible progress[J].J Clin Oncol, 1999, 17(6):1794～1801
  • 2Wistuba Ⅱ, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma[J]. Semin Oncol, 2001, 28(2 Suppl 4):3～13
  • 3Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer [J]. Semin Oncol. 2004, 31(2 Suppl 4):106～111
  • 4Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor[J]. Cancer Res, 1996, 56(2): 370～376
  • 5Rubin BP, Singer S, Tsao C, et al. KIT Activation Is a Ubiquitous feature of gastrointestinal stromal Tumors [J]. Cancer Res,2001, 61(22):8118～8121
  • 6Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications [J]. Clin Cancer Res, 2003, 9(1):188～194
  • 7Burger H, den Bakker MA, Stoter G, et al. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens [J]. EurJ Cancer, 2003, 39(6):793～799
  • 8Mohtashim N, Madhu D, Joseph IC, et al. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis [J]. Hum Pathol, 2002, 33(12):1182～1187
  • 9Laura B, Silvia U, Silvia G, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance [J].Clin Cancer Res, 2004, 10(12): 4101～4108
  • 10Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth [J].Clin Cancer Res, 2000, 6(8): 3319～3326

同被引文献41

  • 1沈文斌（综述）,祝淑钗（审校）,王展宏（校对）.局限期小细胞肺癌脑预防照射研究进展[J].中国肿瘤临床,2006,33(16):956-959. 被引量：3
  • 2Lucchi M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon[J]. Eur j Cardiothorac Surg, 2002,21(6): 1105-1110.
  • 3Spigel DR, Greco FA, Zubkus JD, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-ceil lung cancer[J]. J Thorac Oncol, 2009, 4 (12): 1555-1560.
  • 4Horn L, Dahlberg SE, Sandler AB, et al. Phase Ⅱ study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501[J].J Clin Oncol, 2009, 27(35): 6006-6011.
  • 5Jalal s, Bedano P, Einhorn L, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group [J].J Thorac Oncol, 2010, 5(12): 2008-2011.
  • 6Giditz BJ, Moon j, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase Ⅱ trial[J], J Thorac Oncol, 2010, 5(11): 1835-1840.
  • 7Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial[J], J Natl Cancer Inst, 2009, 101(15): 1049-1057.
  • 8Krug LM, CrapanzanoJP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase Ⅱ clinical trial[J]. Cancer, 2005, 103(10): 2128-2131.
  • 9Johnson FM, Krug LM, Tran HT, et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma[J]. Cancer, 2006, 106(2): 366-374.
  • 10Schneider BJ, Kalemkerian GP, Ranmath N, et al. Phase Ⅱ trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer [J]. Clin Lung Cancer, 2010, 11(4): 223-227.

引证文献2

二级引证文献4

中国肿瘤临床
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部